These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25771380)

  • 1. Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine.
    Pillai AM; Knapp FF
    Curr Radiopharm; 2015; 8(2):78-85. PubMed ID: 25771380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease.
    Knapp FF; Pillai AM
    Curr Radiopharm; 2015; 8(2):77. PubMed ID: 25771381
    [No Abstract]   [Full Text] [Related]  

  • 3. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.
    Bhardwaj R; van der Meer A; Das SK; de Bruin M; Gascon J; Wolterbeek HT; Denkova AG; Serra-Crespo P
    Sci Rep; 2017 Mar; 7():44242. PubMed ID: 28287131
    [No Abstract]   [Full Text] [Related]  

  • 5. Production logistics of 177Lu for radionuclide therapy.
    Pillai MR; Chakraborty S; Das T; Venkatesh M; Ramamoorthy N
    Appl Radiat Isot; 2003; 59(2-3):109-18. PubMed ID: 12941498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).
    Hosono M; Ikebuchi H; Nakamura Y; Nakamura N; Yamada T; Yanagida S; Kitaoka A; Kojima K; Sugano H; Kinuya S; Inoue T; Hatazawa J
    Ann Nucl Med; 2018 Apr; 32(3):217-235. PubMed ID: 29333565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutron-activated theranostic radionuclides for nuclear medicine.
    Tan HY; Yeong CH; Wong YH; McKenzie M; Kasbollah A; Md Shah MN; Perkins AC
    Nucl Med Biol; 2020; 90-91():55-68. PubMed ID: 33039974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
    Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
    Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy.
    Manenti S; Groppi F; Gandini A; Gini L; Abbas K; Holzwarth U; Simonelli F; Bonardi M
    Appl Radiat Isot; 2011 Jan; 69(1):37-45. PubMed ID: 20801665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
    Ahmadzadehfar H; Albers P; Bockisch A; Boegemann M; Böhme C; Burchert W; Dietlein M; Drzezga A; Fabry U; Feldmann G; Heidenreich A; Heinzel A; Herrmann K; Heyll A; Höhling C; Kreuzer C; Laufer D; Mengel R; Mottaghy FM; Müller HW; Müller SC; Ost E; Rahbar K; Reifenhäuser W; Schäfers M; Schlenkhoff C; Schmidt M; Schmidt-Wolf I; Wildenhain C; Zimmer B; Essler M
    Urologe A; 2018 Jun; 57(6):709-713. PubMed ID: 29671080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report from the 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT), Bad Berka (Germany), June 23-26, 2011.
    Jurgilewicz D
    Nucl Med Rev Cent East Eur; 2011; 14(2):125-6. PubMed ID: 22219158
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy.
    Cappon DJ; Fang S; Berry K; Capone G; Carlton GL; Chrétien M; Gough J; Kamen J; Khoorshed A; Miller A; Nelli S; Petric MP; Tourneur F; Zic JJ
    Health Phys; 2023 Feb; 124(2):139-146. PubMed ID: 36508552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of glass microspheres comprising 90Y and (177)Lu for treating of hepatic tumors with SPECT imaging capabilities.
    Poorbaygi H; Reza Aghamiri SM; Sheibani S; Kamali-Asl A; Mohagheghpoor E
    Appl Radiat Isot; 2011 Oct; 69(10):1407-14. PubMed ID: 21723135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept.
    Huclier-Markai S; Alliot C; Kerdjoudj R; Mougin-Degraef M; Chouin N; Haddad F
    Cancer Biother Radiopharm; 2018 Oct; 33(8):316-329. PubMed ID: 30265573
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Rizvi SFA; Naqvi SAR; Roohi S; Sherazi TA; Rasheed R
    Mol Biol Rep; 2018 Dec; 45(6):1759-1767. PubMed ID: 30143975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
    Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
    Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear data for production and medical application of radionuclides: Present status and future needs.
    Qaim SM
    Nucl Med Biol; 2017 Jan; 44():31-49. PubMed ID: 27821344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.
    Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S
    Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.